CCM
PRLD icon

CAAS Capital Management’s Prelude Therapeutics PRLD Stock Holding History

CAAS Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$3.58M – 1352
2020
Q4 		$3.58M Hold
50,000
– – 0.03% 381
2020
Q3 		$1.51M Buy
+50,000
New +$1.41M 0.04% 292

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

CAAS Capital Management's PRLD Position: Q1 2021 in Review

CAAS Capital Management sold out of Prelude Therapeutics (PRLD) in Q1 2021, closing a stake of 50,000 shares — an estimated $3.58M sold.

CAAS Capital Management first reported a position in PRLD in Q3 2020 and held it in 2 quarters. The position peaked at $3.58M in Q4 2020. 60 funds tracked by Wall St. Rank hold PRLD as of Q1 2021.

  • CAAS Capital Management reported no remaining Prelude Therapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 50,000 Prelude Therapeutics shares in Q1 2021, an estimated $3.58M.
  • CAAS Capital Management first reported a position in Prelude Therapeutics in Q3 2020 and held it in 2 quarters.
  • CAAS Capital Management's Prelude Therapeutics position peaked at $3.58M in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.